Report Company Directory

WuXi AppTec Co. Ltd. Class H

• Regional Morning Meeting Notes: Thursday, June 19, 2025 by UOB
• China Healthcare: Entering a new phase of accelerated growth. Upgrade to OVERWEIGHT. by UOB
• China Healthcare: Drug Innovators Continue To Drive Market Growth by UOB
• Greater China Daily: Wednesday, April 30, 2025 by UOB
• WuXi AppTec (2359 HK): 1Q25: Results beat; maintains 10-15% yoy growth target for 2025. by UOB
• China Healthcare: Prefer leading drug innovators and internet healthcare companies amid escalating USChina trade tensions. by UOB
• Greater China Strategy Alpha Picks: April Conviction Calls by UOB
• Greater China Daily: Wednesday, March 19, 2025 by UOB
• Regional Morning Notes - Wednesday, March 19, 2025 by UOB
• WuXi AppTec (2359 HK): 2024: Results satisfactory; targets continued operations for accelerated revenue growth of 10-15% yoy in 2025. by UOB

WUXI AUTOWELL TECHNOLOGY CO LTD

Wuxi Biologics (Cayman) Inc.

• Wuxi Biologics (Cayman) Inc: 1 director by SmartInsider
• China CRO Sector "Biopharma survey: the rising BD, R&D budget and..." by UBS AG
• First Read: Wuxi Biologics "H224 largely in line; early stage R&D..." by UBS AG
• China Equity Strategy "EU stimulus beneficiaries - potential laggard..." by UBS AG
• First Read: China CRO Sector "Trump's call to reshore drug production hurt..." by UBS AG
• Global Strategy "Quantamental Signal Ideas - Top & Bottom Ranked Stocks" Le Roux by UBS AG
• China Healthcare "Weekly recap: NHSA investigation on generic drug quality..." by UBS AG
• Wuxi Biologics "Resilient R&D growth but late-stage CMO requires higher..." by UBS AG
• Global Strategy "Quantamental Signal Ideas - Top & Bottom Ranked Stocks" Le Roux by UBS AG
• China Healthcare "Outlook 2025: Structural opportunities amid uncertainty" Chen by UBS AG

Wuxi Biologics (Cayman) Inc.

• Regional Morning Meeting Notes: Thursday, June 19, 2025 by UOB
• China Healthcare: Entering a new phase of accelerated growth. Upgrade to OVERWEIGHT. by UOB
• China Healthcare: Drug Innovators Continue To Drive Market Growth by UOB
• China Healthcare: Prefer leading drug innovators and internet healthcare companies amid escalating USChina trade tensions. by UOB
• Regional Morning Meeting Notes: Thursday, March 27, 2025 by UOB
• Greater China Daily: Thursday, March 27, 2025 by UOB
• WuXi Biologics (Cayman) (2269 HK): 2024: Results beat, targets accelerated revenue growth in 2025. by UOB
• China Healthcare: Outperformers empowered by AI revolution. by UOB
• Greater China Daily: Thursday, March 28, 2024 by UOB
• China Healthcare: CRDMO leaders take a temporary reprieve, aiming faster growth in 2025. by UOB

WuXi Biologics (Cayman) Inc. TEMP

• Hangzhou Tigermed Consulting "Q420 business update call takeaways" (Buy) Xing by UBS AG
• Hangzhou Tigermed Consulting "Q420 business update call takeaways" (Buy) Xing by UBS AG
• China Healthcare : Potential GPO tender places pressure on orthopaedic producers. by UOB